CANSINOBIO (06185) has announced that its recombinant trivalent poliomyelitis vaccine, utilizing Sf-RVN cells, has obtained approval from China's National Medical Products Administration to initiate clinical trials. This vaccine, crafted through sophisticated protein structure design and virus-like particle (VLP) assembly technology, eliminates viral genetic material entirely and operates independently of live viruses during both production and testing phases. Such features are anticipated to deliver exceptional safety and robust immunogenicity. Notably, the non-infectious VLP-based polio vaccine stands endorsed by the World Health Organization as a premier choice for future polio eradication efforts, positioning it as a potentially ideal solution for the disease's global elimination.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.